Quick-Med Technologies, Inc. (QMDT) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Quick-Med Technologies, Inc. (QMDT) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 57/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 17 mar 2026Quick-Med Technologies, Inc. (QMDT) Resumen de Asistencia Médica y Tuberías
Quick-Med Technologies, Inc. operates in the specialty drug manufacturing sector, focusing on antimicrobial and hemostatic technologies. The company's NIMBUS, Stay Fresh, and MultiStat platforms target diverse applications in healthcare, textiles, and personal care, serving both government and commercial clients with specialized biomedical solutions.
Tesis de Inversión
Quick-Med Technologies, Inc. presents a speculative investment opportunity within the specialty drug manufacturing sector. The company's proprietary NIMBUS, Stay Fresh, and MultiStat technologies offer potential for growth in diverse markets, including healthcare, textiles, and personal care. With a negative P/E ratio of -0.02 and a negative profit margin of -76.8%, the company's financial performance indicates it is not currently profitable. A gross margin of 69.8% suggests strong potential profitability if sales volume increases. Key catalysts include successful commercialization of their technologies and partnerships with larger industry players. However, the company's small size (5 employees) and OTC market listing introduce significant risks related to liquidity and operational scalability. The beta of -39.80 suggests an inverse correlation with the market, but this may be unreliable due to the company's limited trading volume.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Gross Margin of 69.8% indicates strong potential profitability if sales volume increases.
- Negative P/E ratio of -0.02 reflects current lack of profitability.
- Profit Margin of -76.8% indicates significant losses relative to revenue.
- The company has 5 employees, highlighting its small size and potential operational constraints.
- Beta of -39.80 suggests an inverse correlation with the market, but may be unreliable due to limited trading volume.
Competidores y Pares
Fortalezas
- Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.
- Potential for diverse applications in healthcare, textiles, and personal care.
- Existing relationships with government agencies.
- High gross margin (69.8%) indicates potential for profitability.
Debilidades
- Small size and limited resources (5 employees).
- Negative profit margin (-76.8%) indicates significant losses.
- OTC market listing introduces liquidity and regulatory risks.
- Limited brand recognition and market presence.
Catalizadores
- Upcoming: Potential FDA approval for new medical applications of NIMBUS technology (Timeline: 1-2 years).
- Ongoing: Expansion of licensing agreements for Stay Fresh formulation in the textile industry.
- Ongoing: Development of strategic partnerships with larger pharmaceutical companies for commercialization.
- Upcoming: Publication of clinical trial results for MultiStat technology in skin therapy (Timeline: 6-12 months).
Riesgos
- Ongoing: Limited financial resources and negative profitability.
- Potential: Intense competition from larger pharmaceutical and healthcare companies.
- Potential: Stringent regulatory requirements and lengthy approval processes.
- Ongoing: OTC market listing introduces liquidity and regulatory risks.
- Potential: Dependence on key personnel and potential loss of intellectual property.
Oportunidades de crecimiento
- Expansion into the Healthcare Market: Quick-Med's NIMBUS technology, with its antimicrobial and hemostatic properties, can be further developed for wound care and surgical applications. The global wound care market is projected to reach $22 billion by 2028, presenting a significant opportunity for Quick-Med to capture market share through strategic partnerships and product innovation. Timeline: 2-3 years for product development and regulatory approvals.
- Penetration of the Textile Industry: The Stay Fresh formulation offers a durable antimicrobial solution for textiles, addressing the growing demand for hygienic and odor-resistant apparel. The global antimicrobial textiles market is estimated at $10 billion, with increasing adoption in sportswear, healthcare garments, and home textiles. Quick-Med can expand its market presence through collaborations with textile manufacturers and brands. Timeline: 1-2 years for partnership development and product integration.
- Development of Advanced Skin Therapy Products: The MultiStat technology can be leveraged to create innovative skin therapy products targeting various dermatological conditions. The global skin therapy market is projected to reach $40 billion by 2027, driven by increasing consumer awareness and demand for effective skincare solutions. Quick-Med can focus on developing niche products with unique formulations and clinical validation. Timeline: 2-3 years for product development and clinical trials.
- Strategic Partnerships with Government Agencies: Quick-Med can pursue collaborations with government agencies to develop and supply antimicrobial solutions for defense and public health applications. Government contracts offer stable revenue streams and opportunities for long-term growth. The company can leverage its NIMBUS technology to address specific needs in areas such as wound care and infection control. Timeline: Ongoing, with continuous engagement and proposal submissions.
- Licensing and Technology Transfer: Quick-Med can generate revenue by licensing its proprietary technologies to other companies in the healthcare, textile, and personal care industries. Licensing agreements provide a low-risk approach to expanding market reach and generating royalty income. The company can focus on identifying potential licensees with complementary capabilities and market access. Timeline: Ongoing, with continuous evaluation of licensing opportunities.
Oportunidades
- Expansion into the wound care market with NIMBUS technology.
- Penetration of the antimicrobial textiles market with Stay Fresh formulation.
- Development of advanced skin therapy products with MultiStat technology.
- Strategic partnerships with larger industry players for commercialization.
Amenazas
- Intense competition from larger pharmaceutical and healthcare companies.
- Stringent regulatory requirements and lengthy approval processes.
- Pricing pressures and reimbursement challenges.
- Potential for technological obsolescence.
Ventajas competitivas
- Proprietary Technologies: Patented NIMBUS, Stay Fresh, and MultiStat technologies provide a competitive edge.
- Specialized Expertise: Focus on antimicrobial and hemostatic solutions creates a niche market position.
- Established Relationships: Existing relationships with government agencies and healthcare providers offer a stable customer base.
Acerca de QMDT
Founded in 1997 and headquartered in Gainesville, Florida, Quick-Med Technologies, Inc. is a life sciences company dedicated to the research, development, and commercialization of proprietary technologies aimed at the medical and consumer healthcare markets. The company specializes in creating innovative biomedical products and devices with a focus on antibacterial applications. Quick-Med's core technologies include the Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a family of advanced polymers exhibiting antimicrobial and hemostatic properties suitable for various applications. Additionally, they offer Stay Fresh, a chemical formulation designed for textiles, providing durable antimicrobial protection against a broad spectrum of bacteria. Their MultiStat technology represents a collection of patented methods and compounds geared towards advanced skin therapy applications. Quick-Med Technologies serves a diverse clientele, including government agencies, healthcare and medical organizations, apparel and textile manufacturers, and personal care companies, providing them with specialized solutions based on their unique technology platforms. The company's focus on innovation and specialized applications positions it within the niche market of advanced antimicrobial and hemostatic technologies.
Qué hacen
- Develop proprietary antimicrobial technologies.
- Create hemostatic products for medical applications.
- Formulate antimicrobial solutions for textiles.
- Research and develop skin therapy products.
- Serve government agencies with specialized solutions.
- Cater to healthcare and medical companies.
- Provide solutions for the apparel and textile industry.
- Offer products for the personal care market.
Modelo de Negocio
- Develop and patent proprietary technologies in the antimicrobial and hemostatic fields.
- Commercialize these technologies through direct sales to government agencies and healthcare providers.
- License technologies to companies in the textile and personal care industries.
- Generate revenue through product sales, licensing fees, and royalty agreements.
Contexto de la Industria
Quick-Med Technologies operates within the specialty and generic drug manufacturing industry, characterized by intense competition and stringent regulatory requirements. The market is driven by an increasing demand for advanced antimicrobial and hemostatic solutions across healthcare, textiles, and personal care sectors. Companies like Quick-Med differentiate themselves through proprietary technologies and specialized applications. The industry is subject to evolving regulatory standards and pricing pressures, requiring companies to continuously innovate and adapt to maintain competitiveness. The overall drug manufacturing industry is projected to grow, driven by aging populations and increasing healthcare expenditure.
Clientes Clave
- Government agencies requiring antimicrobial solutions.
- Healthcare and medical companies seeking advanced wound care products.
- Apparel and textile manufacturers looking for antimicrobial fabrics.
- Personal care companies developing skin therapy products.
Finanzas
Gráfico e información
Precio de la acción de Quick-Med Technologies, Inc. (QMDT): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 mar 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para QMDT.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para QMDT.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de QMDT en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Gregory S. Schultz
CEO
Gregory S. Schultz serves as the CEO of Quick-Med Technologies, Inc. His background includes experience in managing small teams and guiding the strategic direction of the company. He is responsible for overseeing the development and commercialization of the company's proprietary technologies in the medical and consumer healthcare markets. His leadership is crucial for navigating the challenges of a small company operating in a competitive industry.
Historial: Under Gregory S. Schultz's leadership, Quick-Med Technologies has focused on developing and patenting its core technologies, including NIMBUS, Stay Fresh, and MultiStat. Key milestones include securing government contracts and establishing relationships with healthcare providers. The company has also focused on exploring licensing opportunities to expand its market reach.
Información del mercado OTC de QMDT
The OTC Other tier represents the lowest tier of the OTC market, indicating that Quick-Med Technologies may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud or manipulation. This tier contrasts sharply with exchanges like NYSE or NASDAQ, which have much stricter listing requirements.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited Liquidity: Difficulty in buying or selling shares due to low trading volume.
- Lack of Transparency: Limited financial information and regulatory oversight.
- Price Volatility: Potential for significant price swings due to speculative trading.
- Dilution Risk: Potential for the company to issue new shares, diluting existing shareholders' ownership.
- Going Concern Risk: Uncertainty about the company's ability to continue operating due to financial losses.
- Verify the company's financial statements and SEC filings (if any).
- Research the backgrounds of the company's management team and board members.
- Assess the company's intellectual property and patent portfolio.
- Evaluate the company's competitive landscape and market position.
- Understand the company's business model and revenue streams.
- Determine if the company is subject to any regulatory investigations or legal proceedings.
- Consult with a qualified financial advisor before investing.
- Patented Technologies: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.
- Government Contracts: Existing relationships with government agencies.
- Scientific Publications: Peer-reviewed publications supporting the efficacy of their technologies.
QMDT Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar QMDT?
Quick-Med Technologies, Inc. (QMDT) actualmente tiene una puntuación IA de 57/100, indicando puntuación moderada. Fortaleza clave: Proprietary NIMBUS, Stay Fresh, and MultiStat technologies.. Riesgo principal a monitorear: Ongoing: Limited financial resources and negative profitability.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de QMDT?
QMDT actualmente puntúa 57/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de QMDT?
Los precios de QMDT se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre QMDT?
La cobertura de analistas para QMDT incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en QMDT?
Las categorías de riesgo para QMDT incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Limited financial resources and negative profitability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de QMDT?
La relación P/E para QMDT compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está QMDT sobrevalorada o infravalorada?
Determinar si Quick-Med Technologies, Inc. (QMDT) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de QMDT?
Quick-Med Technologies, Inc. (QMDT) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Limited information available for OTC-listed companies.
- Financial data based on available public information.